AlphaMark Advisors LLC lessened its position in United Therapeutics Co. (NASDAQ:UTHR) by 3.1% in the first quarter, HoldingsChannel.com reports. The firm owned 33,670 shares of the biotechnology company’s stock after selling 1,077 shares during the quarter. United Therapeutics accounts for approximately 1.7% of AlphaMark Advisors LLC’s holdings, making the stock its 17th biggest holding. AlphaMark Advisors LLC’s holdings in United Therapeutics were worth $3,952,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Captrust Financial Advisors raised its stake in United Therapeutics by 384.9% during the fourth quarter. Captrust Financial Advisors now owns 257 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 204 shares during the last quarter. Oregon Public Employees Retirement Fund raised its stake in United Therapeutics by 10,537.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,551,229 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 3,517,845 shares during the last quarter. First Mercantile Trust Co. raised its stake in United Therapeutics by 47.8% during the fourth quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 110 shares during the last quarter. Financial Gravity Companies Inc. purchased a new position in United Therapeutics during the fourth quarter valued at $44,000. Finally, Financial Gravity Wealth Inc. purchased a new position in United Therapeutics during the first quarter valued at $46,000. Institutional investors own 95.13% of the company’s stock.
United Therapeutics stock opened at $87.50 on Monday. The firm has a market capitalization of $3.83 billion, a price-to-earnings ratio of 6.53 and a beta of 1.01. United Therapeutics Co. has a 12 month low of $83.96 and a 12 month high of $130.00. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.19 and a quick ratio of 6.84.
In related news, Director Christopher Patusky sold 3,370 shares of United Therapeutics stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $110.75, for a total value of $373,227.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.20% of the stock is currently owned by company insiders.
A number of research analysts have issued reports on UTHR shares. TheStreet upgraded United Therapeutics from a “c+” rating to a “b-” rating in a research note on Monday, February 11th. BidaskClub cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 31st. Oppenheimer set a $160.00 price objective on United Therapeutics and gave the company a “buy” rating in a research note on Tuesday, March 26th. Wedbush set a $269.00 price objective on United Therapeutics and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, LADENBURG THALM/SH SH set a $124.00 target price on United Therapeutics and gave the stock a “hold” rating in a report on Thursday, February 28th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $129.00.
ILLEGAL ACTIVITY NOTICE: “United Therapeutics Co. (UTHR) Shares Sold by AlphaMark Advisors LLC” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/4353784/united-therapeutics-co-uthr-shares-sold-by-alphamark-advisors-llc.html.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Featured Article: How much can an individual set aside as a catch-up contribution?
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.